Advanced Prostate Cancer VL

The Proteogenomics of Prostate Cancer Radioresistance - Roni Haas

Details
Roni Haas joins Andrea Miyahira to discuss research on prostate cancer radioresistance, focusing on differences between conventional and hypofractionated radiation therapy approaches. The study reveals that conventional radiation treatment, involving multiple small doses over time, leads to a more aggressive radioresistant phenotype with greater mutations and driver gene dysregulation compared to...

Study Reveals How Prostate Cancer Alters Bone Structure, Increasing Fracture Risk - Felipe Eltit Guersetti

Details
Felipe Eltit joins Andrea Miyahira to discuss his research on prostate cancer bone metastases, focusing on their structural characteristics and impact on bone health. His study investigates how these metastases, which occur in 90% of advanced prostate cancer patients, generate osteoblastic lesions that paradoxically lead to bone weakness and pain. Using high-resolution imaging techniques, includin...

Online Platform Maps Theranostic Trials Worldwide for Patients and Physicians - Luke Nordquist

Details
Zachary Klaassen and Luke Nordquist discuss TheranosticTrials.org, a comprehensive global website dedicated to theranostic education and clinical trial information. Dr. Nordquist explains how the platform has expanded from initially covering 150 trials across 12 cancer types to now featuring over 600 trials for 35 different cancers. The website serves as an educational resource for patients, physi...

Polyaneuploid Cancer Cells Drive Metastasis and Resist Treatments in Prostate Cancer - Sarah Amend

Details
Sarah Amend discusses research on polyaneuploid cancer cells (PACCs) and their role in metastasis, published in Molecular Cancer Research. Dr. Amend explains how cancer cells under stress enter an adaptive endocycling state, increasing dramatically in size and genomic content without dividing. The discussion highlights their findings that cells in the PACC state are preferentially found in circula...

VA Study Examines Use of Combination Therapies for mHSPC and Outcomes in Patients - Martin Schoen & Bruce Montgomery

Details
Neeraj Agarwal leads a discussion with Martin Schoen and Bruce Montgomery about a study examining treatment patterns and outcomes for veterans with metastatic hormone-sensitive prostate cancer. The research reveals that VA patients demonstrate longer survival rates compared to the general U.S. population, particularly among younger patients, with combination therapy now being utilized in approxima...

Trial Library Platform Expands Clinical Trial Access for Patients - Hala Borno

Details
Andrea Miyahira interviews Hala Borno about Trial Library, an innovative platform developed to improve access to clinical trials and increase diversity in trial participation. The technology-enabled service connects community providers with clinical trials while offering comprehensive patient navigation support, addressing social determinants of health and practical barriers to trial participation...

RaLu Trial: Sequence of Radium Then Lutetium in mCRPC Management - Kambiz Rahbar

Details
Oliver Sartor and Kambiz Rahbar discuss the RaLu study examining the safety and efficacy of sequential radiopharmaceutical treatments in metastatic castration-resistant prostate cancer. The discussion highlights how lutetium-PSMA therapy can be safely administered following radium treatment, with outcomes consistent across different treatment sequences and timing intervals. They examine how these...

Response and Progression Criteria for PSMA PET: Imaging Prostate Cancer Outcomes - Wolfgang Fendler

Details
Oliver Sartor and Wolfgang Fendler explore the evolving role of PSMA PET imaging in assessing treatment response and progression in prostate cancer. Dr. Fendler outlines two key assessment approaches: the PPP criteria for early-stage disease focusing on lesion numbers, and the RECIP criteria for advanced disease examining tumor volume changes. The conversation highlights how PSMA PET findings corr...

Pelvic Muscle Rehabilitation after Radical Prostatectomy - Diane Newman

Details
Diane Newman delivers a presentation on pelvic floor muscle rehabilitation following radical prostatectomy, highlighting the prevalence and impact of post-surgical urinary incontinence. She explained that while incontinence initially affects 2-90% of patients, most improve within 2-3 months, though 5-20% may experience ongoing symptoms beyond two years. Newman emphasized the importance of pre- and...

Traction Therapy Helps Men Regain Penile Length After Prostate Cancer Treatment - Amy Pearlman

Details
Amy Pearlman discusses penile traction therapy using the RestoreX device, a second-generation technology designed to address penile length changes after prostate cancer treatment. Dr. Pearlman explains how this device, developed by Dr. Landon Trost at Mayo Clinic, offers advantages over first-generation devices through its dynamic stretching capabilities and shorter required usage times. The discu...